TABLE 4.
Serologic status among vaccinated participants, according to selected characteristicsa
| HPV type | No. (%) seropositive having: |
|||||||
|---|---|---|---|---|---|---|---|---|
| Bone marrow transplantb |
Sexual experienceb,c |
Wartsb,d |
Age |
|||||
| Never (n = 9) | Ever (n = 15) | Never (n = 8) | Ever (n = 10) | Never (n = 9/20) | Ever (n = 6/2) | <18 (n = 11) | ≥18 (n = 13) | |
| Low risk, skin | ||||||||
| HPV1 | 6 (67) | 11 (73) | 6 (67) | 4 (67) | 7 (64) | 10 (77) | ||
| HPV2 | 8 (89) | 5 (33)e | 3 (33) | 4 (67) | 6 (55) | 7 (54) | ||
| HPV4 | 4 (44) | 5 (33) | 4 (44) | 2 (33) | 3 (27) | 6 (46) | ||
| Vaccine | ||||||||
| HPV6 | 8 (89) | 14 (93) | 7 (88) | 9 (90) | 18 (90) | 2 (100) | 10 (91) | 12 (92) |
| HPV11 | 8 (89) | 14 (93) | 7 (88) | 9 (90) | 18 (90) | 2 (100) | 10 (91) | 12 (92) |
| HPV16 | 9 (100) | 14 (93) | 7 (88) | 10 (100) | 10 (91) | 13 (100) | ||
| HPV18 | 8 (89) | 10 (67) | 7 (88) | 6 (60) | 9 (82) | 9 (69) | ||
| High risk, mucosal | ||||||||
| HPV52 | 6 (67) | 6 (40) | 4 (50) | 5 (50) | 5 (45) | 7 (54) | ||
| HPV58 | 9 (100) | 7 (47)e | 5 (63) | 7 (70) | 7 (64) | 9 (69) | ||
a
Excludes 3 samples that were BKV seronegative.
b
Restricted to observations with reliable questionnaire data on history of bone marrow transplant, sexual experience, or warts, based on prespecified criteria.
c
Restricted to participants ≥15 years of age.
d
For HPV1, -2, and -4, only common warts were considered (sample size, 9 versus 6). For HPV6 and -11, only genital or anal warts were considered (sample size, 20 versus 2).
e
P < 0.05.